Company profile
Rigel Pharmaceuticals, Inc.
NASDAQ: RIGL · Healthcare · Biotechnology
#253 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
82B+FH 92DQ 72GM 73SS 78
v0.1 · 65/100 weight · provisional
↑ net margin, return on assets · ↓ disclosure history, growth stability
Methodology →Revenue TTM
$299.8M
Rev growth YoY (TTM)
+47.6%
Net income (FY)
$367.0M
Employees
173
as of 2026-08-11
Market cap
$770.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$294.3M$294.3M2025
Net income$367.0M$367.0M2025
Operating income$125.5M$125.5M2025
Total assets$513.6M$513.6M2025
Liabilities$122.1M$122.1M2025
Equity$391.5M$391.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product107%
Contract revenues from collaborations29%
Government Contract0%
Discounts and allowances-36%
By geography
Not disclosed.
The read
What is Rigel Pharmaceuticals, Inc.’s revenue?
Rigel Pharmaceuticals, Inc. booked $294.3M in FY2025 revenue, growing 64% year over year — faster than most Healthcare companies we track, at a 124.7% net margin.
Peers · Healthcare
Evolus, Inc.59CIronwood Pharmaceuticals, Inc.79B+Inogen, Inc.71BAngioDynamics, Inc.72BXeris Biopharma Holdings, Inc.64CAurinia Pharmaceuticals Inc.78B+Neighbors
San Mateo →Key facts
CEORaul R. Rodriguez
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: RIGL
Employees173
IPO date2000-11-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.